Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Z. Ping Lin"'
Publikováno v:
PLoS ONE, Vol 19, Iss 7 (2024)
Externí odkaz:
https://doaj.org/article/b7fbf51be075430f8db959fa0b50ecd8
Publikováno v:
iScience, Vol 26, Iss 10, Pp 107934- (2023)
Summary: Ovarian cancer is the deadliest gynecologic malignancy in women, with a 46% five-year overall survival rate. The objective of the study was to investigate the effects of non-homologous end-joining (NHEJ) genes on clinical outcomes of ovarian
Externí odkaz:
https://doaj.org/article/dea102a4b29e4efca5e206c474b53319
Publikováno v:
Cancers, Vol 15, Iss 15, p 3919 (2023)
Epithelial ovarian cancer (EOC) remains the most lethal gynecologic malignancy, largely due to metastasis and drug resistant recurrences. Fifteen percent of ovarian tumors carry mutations in BRCA1 or BRCA2, rendering them vulnerable to treatment with
Externí odkaz:
https://doaj.org/article/8d825e27faf94a58af376fafc36ae4aa
Autor:
Z. Ping Lin, Nour N. Al Zouabi, Mark L. Xu, Nicole E. Bowen, Terence L. Wu, Ethan S. Lavi, Pamela H. Huang, Yong-Lian Zhu, Baek Kim, Elena S. Ratner
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-21 (2021)
Abstract Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR
Externí odkaz:
https://doaj.org/article/7c21bcf75bea4e2ebab41ede567eddbb
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Ovarian, uterine/endometrial, and cervical cancers are major gynecologic malignancies estimated to cause nearly 30,000 deaths in 2018 in US. Defective cell cycle regulation is the hallmark of cancers underpinning the development and progression of th
Externí odkaz:
https://doaj.org/article/a1734289e7e34dff8ba0db975bd19306
PDF file - 128K, Fig. S1. BRCA1 and BRCA2-defective EOC cells are sensitive to triapine. Fig. S2. Triapine abrogates olaparib-induced RPA phosphorylation in SKOV-3 cells. Fig. S3. Depletion of Chk1 partially reverses the inhibitory effects of triapin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::400104c13344c75041cfa88b2687f829
https://doi.org/10.1158/1541-7786.22512162
https://doi.org/10.1158/1541-7786.22512162
PARP inhibitors exploit synthetic lethality to target epithelial ovarian cancer (EOC) with hereditary BRCA mutations and defects in homologous recombination repair (HRR). However, such an approach is limited to a small subset of EOC patients and comp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::85d0308a08beb1172166e9cde7efeb34
https://doi.org/10.1158/1541-7786.c.6540153.v1
https://doi.org/10.1158/1541-7786.c.6540153.v1
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2255
Phenotypic analysis of the effects of a gene of interest may be limited because stable expression of some genes leads to adverse consequences in cell survival, such as disturbance of cell cycle progression, senescence, autophagy, and programmed cell
Autor:
Pamela H Huang, Nicole E. Bowen, Baek Kim, Nour N Al Zouabi, Mark L Xu, Terence L. Wu, Yong-Lian Zhu, Elena Ratner, Z. Ping Lin, Ethan S Lavi
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-21 (2021)
Scientific Reports
Scientific Reports
Poly ADP-ribose polymerase (PARP) inhibitors are promising targeted therapy for epithelial ovarian cancer (EOC) with BRCA mutations or defective homologous recombination (HR) repair. However, reversion of BRCA mutation and restoration of HR repair in
Publikováno v:
Methods in Molecular Biology ISBN: 9781071611616
Phenotypic analysis of the effects of a gene of interest may be limited because stable expression of some genes leads to adverse consequences in cell survival, such as disturbance of cell cycle progression, senescence, autophagy, and programmed cell
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::79b57ba20a1a243de8f613aaffb89eed
https://doi.org/10.1007/978-1-0716-1162-3_5
https://doi.org/10.1007/978-1-0716-1162-3_5